BR112012000079A2 - derivados fluorados de 3-hidroxipiridin-4-onas - Google Patents

derivados fluorados de 3-hidroxipiridin-4-onas

Info

Publication number
BR112012000079A2
BR112012000079A2 BR112012000079A BR112012000079A BR112012000079A2 BR 112012000079 A2 BR112012000079 A2 BR 112012000079A2 BR 112012000079 A BR112012000079 A BR 112012000079A BR 112012000079 A BR112012000079 A BR 112012000079A BR 112012000079 A2 BR112012000079 A2 BR 112012000079A2
Authority
BR
Brazil
Prior art keywords
hydroxypyridin
ones
fluorinated derivatives
fluorinated
derivatives
Prior art date
Application number
BR112012000079A
Other languages
English (en)
Inventor
Shah Birenkumar
N'zemba Blaise
Maria Wodzinska Jolanta
Premyslova Maryna
Leung-Toung Regis
Xin Tao
Fat Tam Tim
Zhao Yanqing
Wang Yingsheng
Original Assignee
Apotex Tech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43410413&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112012000079(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Apotex Tech Inc filed Critical Apotex Tech Inc
Publication of BR112012000079A2 publication Critical patent/BR112012000079A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/69—Two or more oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/26—Radicals substituted by halogen atoms or nitro radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/86—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/86—Oxygen atoms
    • C07D211/88—Oxygen atoms attached in positions 2 and 6, e.g. glutarimide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
BR112012000079A 2009-07-03 2010-07-05 derivados fluorados de 3-hidroxipiridin-4-onas BR112012000079A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22297909P 2009-07-03 2009-07-03
PCT/CA2010/001027 WO2011000104A1 (en) 2009-07-03 2010-07-05 Fluorinated derivatives of 3-hydroxypyridin-4-ones

Publications (1)

Publication Number Publication Date
BR112012000079A2 true BR112012000079A2 (pt) 2017-07-25

Family

ID=43410413

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012000079A BR112012000079A2 (pt) 2009-07-03 2010-07-05 derivados fluorados de 3-hidroxipiridin-4-onas

Country Status (34)

Country Link
US (6) US9073865B2 (pt)
EP (1) EP2448922B1 (pt)
JP (1) JP5611339B2 (pt)
KR (1) KR101682966B1 (pt)
CN (2) CN102712591B (pt)
AU (1) AU2010268666B2 (pt)
BR (1) BR112012000079A2 (pt)
CA (1) CA2767130C (pt)
CL (1) CL2012000009A1 (pt)
CY (1) CY1115632T1 (pt)
DK (1) DK2448922T3 (pt)
EA (1) EA020976B1 (pt)
EC (1) ECSP12011648A (pt)
ES (1) ES2524342T3 (pt)
GE (1) GEP20146008B (pt)
HK (1) HK1173139A1 (pt)
HR (1) HRP20141051T1 (pt)
IL (1) IL217349A (pt)
MA (1) MA33985B1 (pt)
ME (1) ME01911B (pt)
MX (1) MX2012000247A (pt)
MY (1) MY163058A (pt)
NI (1) NI201200004A (pt)
NZ (1) NZ597893A (pt)
PE (1) PE20120924A1 (pt)
PL (1) PL2448922T3 (pt)
PT (1) PT2448922E (pt)
RS (1) RS53642B1 (pt)
SG (1) SG177462A1 (pt)
SI (1) SI2448922T1 (pt)
TN (1) TN2011000678A1 (pt)
UA (1) UA108076C2 (pt)
WO (1) WO2011000104A1 (pt)
ZA (1) ZA201200751B (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112552232B (zh) * 2020-12-16 2022-11-25 浙江工业大学 一种吡啶酮六位炔胺修饰衍生物及其制备方法与应用
CN115144480B (zh) * 2021-03-31 2023-11-28 成都倍特药业股份有限公司 一种从罗沙司他中间体中检测吗啉和/或四甲基甲烷二胺的方法

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2918402A (en) 1958-07-29 1959-12-22 Dodge Chem Co Bactericidal-fungicidal compositions
NL300788A (pt) 1962-12-20
CA1095921A (en) 1976-08-02 1981-02-17 Thomas M. Brennan Preparation of gamma-pyrones
GB8308055D0 (en) * 1983-03-24 1983-05-05 Hider R C Pharmaceutical compositions
GB8308054D0 (en) * 1983-03-24 1983-05-05 Hider R C Pharmaceutical compositions
USRE34313E (en) 1983-09-23 1993-07-13 National Research Development Corporation Pharmaceutical compositions
GB8325496D0 (en) 1983-09-23 1983-10-26 Hider R C Pharmaceutical compositions
GB8329043D0 (en) * 1983-10-31 1983-11-30 Hider R C Pharmaceutical compositions
EP0336369A1 (en) 1988-04-04 1989-10-11 E.R. Squibb & Sons, Inc. 3-Acylamino-1-[[[(substituted sulfonyl)amino]carbonyl]amino]2-azetidinones
DE3826846A1 (de) * 1988-08-06 1990-02-08 Goedecke Ag Alkoxy-4(1h)-pyridon-derivate, verfahren zu deren herstellung und deren verwendung als arzneimittel
JPH0714872B2 (ja) 1990-02-06 1995-02-22 昭和薬品化工株式会社 シロップ剤組成物
GB9100465D0 (en) 1991-01-09 1991-02-20 Hider Robert C Pharmaceutical compositions
US5624807A (en) 1992-07-22 1997-04-29 The Mclean Hospital Corporation Methods for detecting Alzheimer's disease by measuring ratios of calcium-activated neutral protease isoforms
NO941358L (no) 1993-04-16 1994-10-17 Mcneil Ppc Inc Vandig farmasöytisk suspensjon og fremgangsmåte for fremstilling derav
CA2181463A1 (en) * 1994-01-31 1995-08-03 Fu-Ning Fung Method of synthesizing gamma pyrones
JP2001508755A (ja) 1994-04-08 2001-07-03 ザ、プロクター、エンド、ギャンブル、カンパニー 哺乳動物でラジカルダメージを減少させるために鉄キレート化合物を用いる方法
CA2172807C (en) 1994-08-01 1999-10-12 Keith S. Lienhop Tastemasked liquid pharmaceutical delivery system
US5616621A (en) 1995-01-30 1997-04-01 American Home Products Corporation Taste masking liquids
JPH0925234A (ja) 1995-07-12 1997-01-28 Wakunaga Pharmaceut Co Ltd 脳疾患改善剤
ATE299135T1 (de) * 1995-09-29 2005-07-15 Novartis Pharma Gmbh Hydroxypyridinone
US5763449A (en) 1996-08-07 1998-06-09 Ascent Pediatrics, Inc. Pleasant-tasting aqueous liquid composition of a bitter-tasting drug
GB9711093D0 (en) 1997-05-29 1997-07-23 British Tech Group Novel orally active iron (III) chelators
KR100746753B1 (ko) 1998-08-28 2007-08-06 에자이 알앤드디 매니지먼트 가부시키가이샤 고미 등을 경감한 의약조성물
US6472378B2 (en) 1998-08-31 2002-10-29 Pro-Neuron, Inc. Compositions and methods for treatment of mitochondrial diseases
US6133322A (en) 1998-10-29 2000-10-17 Institut National De La Sante Et De La Recherche Medicale (Inserm) Quinone derivatives for treating or preventing diseases associated with iron overload
US6933104B1 (en) 1999-04-23 2005-08-23 Shiva Biomedical, Llc Diagnosis and treatment of human kidney diseases
IL130324A0 (en) 1999-06-07 2000-06-01 Yeda Res & Dev Pharmaceutical compositions comprising iron chelators for the treatment of neurodegenerative disorders and some novel iron chelators
AUPQ262499A0 (en) 1999-09-02 1999-09-23 University Of Queensland, The Novel iron chelators
CA2313270C (en) 2000-06-30 2011-09-13 Apotex Inc. Use of deferiprone in treating and preventing iron-induced cardiac disease
WO2002072102A1 (en) 2001-03-05 2002-09-19 Ortho-Mcneil Pharmaceutical, Inc. Taste masked liquid pharmaceutical compositions
WO2003075910A1 (en) 2002-03-08 2003-09-18 Protemix Corporation Limited Preventing and/or treating vascular disease, cardiomyopathy and/or associated heart failure
MXPA04008720A (es) 2002-03-12 2004-12-06 Squibb Bristol Myers Co Suspension oral de sabor agradable y metodo.
AU2003251920A1 (en) * 2002-07-12 2004-02-02 The Buck Institute For Research On Aging Iron sequestration or elimination to reduce neurodegeneration or parkinsons disease progression
EP1565185A4 (en) 2002-11-07 2011-01-05 Technion Res & Dev Foundation NEUROPROTECTIVE IRON CHELATORS AND PHARMACEUTICAL COMPOSITIONS THEREWITH
DE10336497B4 (de) 2003-08-08 2007-04-05 Freie Universität Berlin Substituierte Pyridine und ein Verfahren zur Herstellung von substituierten Pyridinen
CN1980574A (zh) 2004-05-06 2007-06-13 锡德克斯公司 包含舍曲林和磺基烷基醚环糊精的掩味的制剂
JP2008500347A (ja) 2004-05-24 2008-01-10 ニュー・ヨーク・ユニヴァーシティー 高血糖症による血糖の急激な増加及び／又は急激な遊離脂肪酸流動の増加の病理学的影響の治療方法又は予防方法
US9737511B2 (en) 2004-05-24 2017-08-22 Geoffrey C. GURTNER Method of treating or preventing pathologic effects of acute increases in hyperglycemia and/or acute increases of free fatty acid flux
US7728038B2 (en) 2004-08-04 2010-06-01 University Of Utah Research Foundation Methods for chelation therapy
US20060093630A1 (en) 2004-10-29 2006-05-04 Buehler Gail K Dye-free pharmaceutical suspensions and related methods
US20070197469A1 (en) 2006-02-17 2007-08-23 Murthy Yerramilli V Fluoroquinolone carboxylic acid salt compositions
MY151412A (en) 2006-02-22 2014-05-30 Munnich Arnold The use of deferiprone and methods to treat and/or prevent friedreich ataxia resulting from intracellular mishandling of iron
PE20081596A1 (es) * 2007-03-28 2009-02-05 Apotex Technologies Inc Derivados fluorinados de deferiprona
GB0803019D0 (en) * 2008-02-19 2008-03-26 Btg Int Ltd Fluorinated compounds
KR101490721B1 (ko) 2008-04-25 2015-02-06 아포텍스 테크놀로지스 인크. 감칠맛을 가진 디페리프론용 액상 제제

Also Published As

Publication number Publication date
EA201270119A1 (ru) 2012-07-30
CN102712591A (zh) 2012-10-03
IL217349A (en) 2015-08-31
US20150335626A1 (en) 2015-11-26
CN103601673A (zh) 2014-02-26
EP2448922B1 (en) 2014-08-20
NI201200004A (es) 2013-06-12
EP2448922A4 (en) 2012-12-19
US20170247329A1 (en) 2017-08-31
CN103601673B (zh) 2016-03-16
AU2010268666B2 (en) 2014-07-24
CY1115632T1 (el) 2017-01-04
ZA201200751B (en) 2012-10-31
NZ597893A (en) 2013-01-25
PT2448922E (pt) 2014-12-02
HK1173139A1 (en) 2013-05-10
WO2011000104A1 (en) 2011-01-06
US9073865B2 (en) 2015-07-07
ME01911B (me) 2014-12-20
JP5611339B2 (ja) 2014-10-22
SI2448922T1 (sl) 2014-12-31
SG177462A1 (en) 2012-02-28
ES2524342T3 (es) 2014-12-05
US9550733B2 (en) 2017-01-24
CA2767130C (en) 2017-08-22
JP2012531468A (ja) 2012-12-10
GEP20146008B (en) 2014-01-10
US9938240B2 (en) 2018-04-10
MX2012000247A (es) 2012-03-26
UA108076C2 (ru) 2015-03-25
DK2448922T3 (da) 2014-11-10
HRP20141051T1 (hr) 2014-12-19
US20160083346A1 (en) 2016-03-24
PL2448922T3 (pl) 2015-02-27
CA2767130A1 (en) 2011-01-06
KR101682966B1 (ko) 2016-12-06
CN102712591B (zh) 2014-06-25
AU2010268666A1 (en) 2012-02-23
KR20120093822A (ko) 2012-08-23
RS53642B1 (en) 2015-04-30
MA33985B1 (fr) 2013-02-01
CL2012000009A1 (es) 2012-07-06
IL217349A0 (en) 2012-02-29
EP2448922A1 (en) 2012-05-09
EA020976B1 (ru) 2015-03-31
US20170088518A1 (en) 2017-03-30
US20120270882A1 (en) 2012-10-25
MY163058A (en) 2017-08-15
US20150274665A1 (en) 2015-10-01
PE20120924A1 (es) 2012-08-19
ECSP12011648A (es) 2012-07-31
TN2011000678A1 (en) 2013-05-24

Similar Documents

Publication Publication Date Title
SMT201600075B (it) Composto di diamminocarbossammide eterociclica
DOP2012000114A (es) Inhibidor bromodominio de benzodiazepina
BRPI1013246A2 (pt) derivados de benzofuralina
BR112012002828A2 (pt) derivados de 5-fluorpirimidinona
ECSP12011999A (es) Derivados benzamida sustituidos
BRPI1010738A2 (pt) derivados de aminotriazol fluorado
BRPI1013844A2 (pt) derivados de piridina-isoxazol
DK2397480T3 (da) Diazepindionderivat
BRPI1008744A2 (pt) hidrotratamento de caboidratos
BRPI1014454A2 (pt) derivados de isoxazol-pirazol
SMT201600076B (it) Derivati di 2-osso-1-pirrolidinil imidazotiadiazolo
DK2387580T3 (da) Deoxyactagardinderivater
SMT201500268B (it) Derivato di 5-idrossipirimidin-4-carbossammide
BRPI1014688A2 (pt) aplicações terapêuticas de derivados de quinazolinadiona
BR112012002810A2 (pt) derivados de n1-acil-5-fluoropirimidinona
BRPI1011416A2 (pt) derivados de antraquinova novos
IT1398296B1 (it) Disposizione di sensori
BR112012002971A2 (pt) preparação regioseletiva de derivados 2-amino-5-trifluorometil-pirmidinas
BR112012002807A2 (pt) derivados de 5-flúor-2-oxopirimidina-1(2h)-caboxilato
DK2453858T3 (da) Fremgangsmåde
CU23884B1 (es) Derivados de dibenzotiazepina
BR112012000079A2 (pt) derivados fluorados de 3-hidroxipiridin-4-onas
FI20095315A0 (fi) Iskulaite
FR2950090B1 (fr) Exutoire de fumee
UY33133A (es) Nuevos derivados de piridazina

Legal Events

Date Code Title Description
B15I Others concerning applications: loss of priority
B12F Other appeals [chapter 12.6 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11T Dismissal of application maintained [chapter 11.20 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]